Statins, hormones, and women: Benefits and drawbacks for atherosclerosis and osteoporosis
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Clinical trials have shown that 3-hydoxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, known as statins, significantly reduce the risk of both primary and secondary coronary heart disease events. Although these trials have included few women, the evidence suggests that statins are as effective in women as in men. The addition of hormone replacement therapy to statin therapy augments lowering of low-density lipoprotein cholesterol, but may not increase the favorable effects on clinical events achieved with statins alone. Finally, new data suggest that statins may also reduce the risk of osteoporotic fractures, a provocative finding still in need of verification by clinical trials.
- Maron DJ, Fazio S, Linton MF: Current perspectives on statins. Circulation 2000, 101:207–213.
- Ross R: Atherosclerosis—an inflammatory disease. N Engl J Med 1999, 340:115–126. CrossRef
- Bellosta S, Ferri N, Bernini F, et al.: Non-lipid-related effects of statins. Ann Med 2000, 32:164–176.
- Raiteri M, Arnaboldi L, McGeady P, et al.: Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation. J Pharmacol Exp Ther 1997, 281:1144–1153.
- Laufs U, Liao JK: Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998, 273:24266–24271. CrossRef
- Cummings SR, Bauer DC: Do statins prevent both cardiovascular disease and fracture? JAMA 2000, 283:3255–3257. CrossRef
- Russell RG, Rogers MJ, Frith JC, et al.: The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res 1999, 14(Suppl 2):53–65.
- Reszka AA, Halasy-Nagy JM, Masarachia PJ, Rodan GA: Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mstl kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem 1999, 274:34967–34973. CrossRef
- Fisher JE, Rogers MJ, Halasy JM, et al.: Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 1999, 96:133–138. CrossRef
- Mundy G, Garrett R, Harris S, et al.: Stimulation of bone formation in vitro and in rodents by statins. Science 1999, 286:1946–1949. CrossRef
- Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301–1307. CrossRef
- Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998, 279:1615–1622. CrossRef
- Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383–1389. CrossRef
- Sacks FM, Pfeffer MA, Moye LE, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001–1009. CrossRef
- Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349–1357. CrossRef
- Sacks FM, Tonkin AM, Shepherd J, et al.: Effect of pravastatin on coronary disease risk events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project. Circulation 2000, 102:1893–1900.
- LaRosa JC, He J, Vupputuri S: Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials. JAMA 1999, 282:2340–2346. CrossRef
- Gerhard M, Ganz P: How do we explain the clinical benefits of estrogen? From bedside to bench. Circulation 1995, 92:5–8.
- Hulley S, Grady D, Bush T, et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998, 280:605–613. CrossRef
- Herrington DM, Reboussin DM, Brosnihan KB, et al.: Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000, 343:522–529. CrossRef
- Grady D, Wenger NK, Herrington DM, et al.: Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000, 139:689–696.
- Colditz GA, Hankinson SE, Hunter DJ, et al.: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995, 332:1589–1593. CrossRef
- Darling GM, Johns JA, McCloud PI, Davis SR: Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997, 337:595–601. CrossRef
- Sbarouni E, Kyriakides ZS, Kremastinos DT: The effect of hormone replacement therapy alone or in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease. J Am Coll Cardiol 1998, 32:1244–1250. CrossRef
- Herrington DM, Werbel BL, Riley WA, et al.: Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease. J Am Coll Cardiol 1999, 33:2030–2037. CrossRef
- Ohta H, Komukai S, Sugimoto I, et al.: Effect of a HMG-CoA reductase inhibitor combined with hormone replacement therapy on lipid metabolism in Japanese women with hypoestrogenic lipidemia: a multicenter double-blind controlled prospective study. Maturitas 1998, 29:163–171. CrossRef
- Davidson MH, Testolin LM, Maki KC, et al.: A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women. Arch Intern Med 1997, 157:1186–1192. CrossRef
- Herrington DM, Vittinghoff E, Hunninghake D, et al.: Effects of statin therapy on cardiovascular events and all-cause mortality in women in the Heart and Estrogen/progestin Replacement Study (HERS) (abstract). Circulation 2000, 102 (Suppl):II-837.
- Chan KA, Andrade SE, Boles M, et al.: Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 2000, 355:2185–2188. CrossRef
- Wang PS, Solomon DH, Mogun H, Avorn J: HMG-CoA reductase inhibitors and the risk of hip fractures in the elderly. JAMA 2000, 283:3211–3216. CrossRef
- Meier CR, Schlienger RG, Kraenzlin ME, et al.: HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000, 283:3205–3210. CrossRef
- Van Staa TP, Wegman SL, de Vries F, et al.: Use of statins and risk of fractures [abstract]. J Bone Miner Res 2000, 15(Suppl 1):S155.
- Bauer DC, Mundy GR, Jamal SA, et al.: Statin use, bone mass and fracture: an analysis of two prospective studies [abstract]. J Bone Miner Res 1999, 14(Suppl):S179.
- LaCroix AZ, Cauley JA, Jackson R, et al.: Does statin use reduce risk of fracture in postmenopausal women? Results from the Women’s Health Initiative Observational Study [abstract]. J Bone Miner Res 2000, 15(Suppl 1):S155.
- Reid IR, Hague W: Effect of pravastatin on fracture incidence in the Lipid Study: a randomized controlled trial [abstract]. J Bone Miner Res 2000, 15(Suppl 1):S225.
- El-Sohemy A: Statin drugs and the risk of fracture [letter]. JAMA 2000, 284:1921. CrossRef
- Pedersen TR, Kjekshus J: Statin drugs and the risk of fracture [letter]. JAMA 2000, 284:1921–1922. CrossRef
- Edwards CJ, Hart DJ, Spector TD: Oral statins and increased bone-mineral density in postmenopausal women. Lancet 2000, 355:2218–2219. CrossRef
- Cauley JA, Jackson R, Pettinger M, et al.: Statin use and bone mineral density (BMD) in older women: the Women’s Health Initiative Observational Study [abstract]. J Bone Miner Res 2000, 15(Suppl 1):S155.
- Chung YS, Lee MD, Lee SK, et al.: HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 2000, 85:1137–1142. CrossRef
- Bjarnason NH, Shalmi M, Riis BJ, Christiansen C: No clinically relevant effect of fluvastatin on postmenopausal bone remodeling [abstract]. J Bone Miner Res 2000, 15(Suppl 1):S427.
- Watanabe S, Fukumoto S, Takeuchi Y, et al.: Effects of one year treatment with statins on bone mass and metabolism [abstract]. J Bone Miner Res 2000, 15(Suppl 1):S194.
- Statins, hormones, and women: Benefits and drawbacks for atherosclerosis and osteoporosis
Current Atherosclerosis Reports
Volume 3, Issue 1 , pp 35-42
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links